Trial reportBreast cancer research and treatment2014
Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study.
Trial report in Breast cancer research and treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01377363 (Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis), which is not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Pooled it
- Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?The oncologist · 2014Pooled it
- TIM3Cancer cell · 2025Article
- Assessment ofHealth science reports · 2025Article
- Estrogen-Receptor Loss andCancers · 2024Article
- Oncotype DX in Breast Cancer Management: Insights and Outcomes From the United Arab Emirates.Cureus · 2024Article
- Article
- Clinical and Translational Applications of Serological and Histopathological Biomarkers in Metastatic Breast Cancer: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells.Cell death and differentiation · 2023Article
- Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors.Frontiers in oncology · 2023Article
- Article
- The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.Breast cancer research and treatment · 2022Article
- Gene expression profiles of breast cancer metastasis according to organ site.Molecular oncology · 2022Article
- Review
- Article
- Mitochondrial DNA analysis efficiently contributes to the identification of metastatic contralateral breast cancers.Journal of cancer research and clinical oncology · 2021Article
- Receptor Discordance of Metastatic Breast Cancer Depending on the Molecular Subtype.Breast care (Basel, Switzerland) · 2020Article
- FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.The Journal of clinical investigation · 2020Article
- Genomic Signatures in Luminal Breast Cancer.Breast care (Basel, Switzerland) · 2020Review
- A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts.EJNMMI research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 17 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) between primary tumors and metastatic lesions in advanced breast cancer. Patients with suspected diagnosis of locally recurrent or metastatic breast cancer, either at first relapse or after successive disease progressions, who had an appropriately preserved sample from a primary tumor and were scheduled for a biopsy of the recurrent lesion, were included. Blinded determinations of receptor status on paired samples were performed by immunohistochemistry and fluorescence in situ hybridization at a central laboratory and compared with those performed locally. Overall, 196 patients were included and 184 patients were considered evaluable. Reasons for non-evaluability included the inability to perform biopsy (n = 4) or biopsy results showing normal tissue (n = 3), benign disease (n = 3) or a second neoplasia (n = 2). Conversion rates determined at local level were higher than those determined centrally (HER2: 16 vs. 3 %, ER: 21 vs. 13 %, PR: 35 vs. 28 %, respectively). There was substantial agreement regarding the expression of HER2 in primary tumors and metastases, and ER at metastases, between local and central laboratories. PR at any site and ER at primary site showed moderate agreement. Oncologists altered their treatment plans in 31 % of patients whose tumor subtype had changed. These results reinforce the recommendation for performing confirmatory biopsies of metastases, not only to avoid misdiagnosis of breast cancer relapse, but also to optimize treatment (clinicaltrials.gov identifier: NCT01377363).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.